No Data
No Data
ST Tiansheng: 2024 Semi-Annual Report
ST Tiansheng: 2024 Semi-Annual Report Summary
Tiansheng Pharmaceutical Group: 2024 Interim Performance Forecast
Tiansheng Pharmaceutical Group (002872.SZ): expected to lose RMB 40 million to 56 million in the first half of the year.
Tiansheng Pharmaceutical Group (002872.SZ) announced on July 9 that it is expected to suffer a loss of 400 to 560 million yuan in the first half of the year, with a non-net loss of 430 to 600 million yuan. The main reason for the company's performance loss during the reporting period is higher fixed costs such as fixed asset depreciation and labor costs.
ST Tiansheng (002872.SZ) announced first-quarter results with a net loss of 20.46 million yuan
According to the Zhitong Finance App, ST Tiansheng (002872.SZ) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved revenue of 148 million yuan, a year-on-year decrease of 5.98%; a net profit loss of 20.46 million yuan to mother; and a loss of 22.36 million yuan in non-net profit. Basic earnings per share - $0.0643.
ST Tiansheng (002872.SZ): Expected net loss of 75 million yuan to 105 million yuan in 2023
Gelonghui, January 30 | ST Tiansheng (002872.SZ) announced that it is expected to have a net loss of 75.0 million yuan to 10,500,000 yuan in 2023, after deducting non-net loss of 95.0 million yuan to 130.0 million yuan, and operating income of 520.00 million yuan to 615.00 million yuan. The main reason for the loss in the company's performance during the reporting period was insufficient capacity utilization of the new production line and high fixed costs such as depreciation of fixed assets and labor costs.
No Data
No Data